FDA warning letters
A warning letter is FDA's formal notice that a company broke the law, usually found during an inspection. The company has 15 working days to reply. Letters that go unanswered lead to seizures, import bans or court orders.
68 letters match. Newest first.
-
Drugswww.weightcrunchshop.com
FDA warned www.weightcrunchshop.com about selling unapproved and misbranded semaglutide and oxycodone drugs to U.S. consumers online.
High risk -
DrugsEugia Pharma Specialities Limited
FDA cited Eugia Pharma Specialities for CGMP violations at its India sterile injectable plant, including falsified records and contamination risks.
High risk -
BiologicsAkan Biosciences, Inc.
FDA warned Akan Biosciences over unapproved Ayama injectable and donor-screening failures.
High risk -
DrugsQuVa Pharma, Inc.
FDA warned QuVa Pharma, a sterile drug outsourcing facility in Bloomsbury, NJ, of mold in its cleanest filling area and other CGMP failures.
High risk -
DrugsIntas Pharmaceuticals Limited
FDA cited Intas Pharmaceuticals for CGMP violations, including manipulated visual inspection records and inadequate sterile-drug controls.
High risk -
DrugsSun Pharmaceutical Industries Ltd.
FDA warns Sun Pharmaceutical over CGMP violations in sterile injectable manufacturing at its Halol, India facility.
High risk -
DrugsSouthern Tier Home Infusion, Inc. dba Pharmacy Innovations
FDA warned compounding pharmacy Pharmacy Innovations that its sterile drugs were made under insanitary conditions and without valid patient prescriptions.
High risk -
DrugsBaxter Healthcare Corporation
FDA warned Baxter over CGMP violations at its India plant, including inadequate endotoxin and visual inspection investigations for sterile injectables.
High risk -
DrugsWarrior Labz SARMS
FDA warned Warrior Labz SARMS that it sells unapproved new drugs, including SARMs and injectables, with drug claims online.
High risk -
DrugsNorth American Custom Laboratories, LLC dba FarmaKeio Superior Custom Compounding
FarmaKeio, a Texas compounding pharmacy, made sterile drugs under insanitary conditions that put patients at risk.
High risk -
BiologicsInvitrx Therapeutics, Inc.
Invitrx Therapeutics made unapproved umbilical cord and exosome products and had serious manufacturing deviations.
High risk -
DrugsAbraxis Bioscience LLC
FDA warned Abraxis Bioscience about repeated contamination in media fills for sterile Abraxane at its Phoenix plant.
High risk -
DrugsNephron SC Inc.
Nephron SC's sterile drug manufacturing had unresolved cross-contamination and microbial contamination, making its drugs adulterated.
High risk -
DrugsGreen Wave Analytical, LLC
FDA warned Green Wave Analytical, a contract drug testing lab, over quality violations and its denied inspection access.
High risk -
BiologicsRe-Gen Active Lab, Inc.
FDA warned Re-Gen Active Lab over unapproved amniotic/umbilical cord injectables and serious sterility failures.
High risk -
DrugsHybrid Pharma, LLC
FDA warned outsourcing facility Hybrid Pharma of Deerfield Beach, Florida, that sterile compounding violations made its drugs adulterated and unapproved.
High risk -
DrugsEmpower Clinic Services, LLC dba Empower Pharmacy
FDA warns Empower Pharmacy its compounded drugs missed outsourcing-facility conditions, including labeling and adverse-event reporting.
Medium -
DrugsToyobo Co. Ltd.
FDA warned Toyobo after inspection found unresolved particulate contamination and environmental monitoring data manipulation affecting sterile injectable drugs.
High risk